Research and innovation
Researching and developing innovative and proprietary pharmaceutical products designed to better manage cardiometabolic disorders is Acasti’s main focus.
Currently, Acasti has a leading prescription drug candidate, CaPre®, and a commercialized medical food product, Onemia®
Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation.
Find the latest articles and news about us! Find out about our recent announcements and quarterly results.